濮阳东方医院看妇科收费不高(濮阳东方妇科咨询专家热线) (今日更新中)

BEIJING, Feb. 11 (Xinhua) -- China's foreign exchange regulator said Friday it did not suffer any losses from its investment in Fannie Mae and Freddie Mac bonds, adding that media reports of up to 450 billion U.S. dollars of losses were "groundless.""Up until now, the capital and interest repayments of Fannie Mae and Freddie Mac bonds is normal, and no losses have incurred," The State Administration of Foreign Exchange (SAFE) said on its website.Annual yields of the bonds were around 6 percent between 2008 and 2010, the SAFE said.The regulator, which oversees China's more than 2 trillion U.S. dollars of foreign exchange reserve, also clarifies it had not bought any stocks of the two troubled mortgage companies.UPI reported on Friday that the Obama Administration will propose phasing out the two mortgage giants after rescuing them, which is part of a U.S. Treasury Department white paper to Congress that lays out three ways of cutting government support to the 10.6 trillion U.S. dollars mortgage market.

WASHINGTON, April 29 (Xinhua) -- A U.S. appeals court ruled on Friday that the Obama administration can continue the taxpayer- funding for human embryonic stem cell research.The U.S. Court of Appeals in Washington overturned a preliminary federal court order that would have blocked the U.S. Health and Human Services Department and the National Institutes of Health (NIH) from spending government money on embryonic stem cells research."Today's ruling is a victory for our scientists and patients around the world who stand to benefit from the groundbreaking medical research they're pursuing," said Nicholas Papas, a White House spokesman.U.S. President Barack Obama has been trying to expand government funding for human embryonic stem cells research, saying that years of progress on finding cures for spinal cord injuries, Parkinson's disease and other diseases would be lost without the government support on this field.Opponents have been arguing the research is unacceptable because embryonic stem cells can only be obtained through destroying human embryos.Last August, a federal judge ruled that the government-backed embryonic stem cell research violated the law because embryos were destroyed in the process and it jeopardized the position of researchers using adult stem cells for winning federal grants.The government immediately appealed to the ruling, and the appeals court said the research could continue at the NIH before the judge ruled on the case.

BEIJING, Feb. 3 (Xinhua) -- Chinese Foreign Ministry said here Thursday that almost all Chinese travellers stranded in Egypt had returned home by planes sent by the government.A total of 1,848 Chinese, including those from Hong Kong, Macao and Taiwan, had been flown back by Thursday afternoon, the ministry said in a statement.The Chinese government has organized eight flights from four Chinese airline companies to Egypt since Jan. 31.The last two planes, belonging to China Eastern Airlines, returned to Beijing from Egypt Thursday, bringing back a total of 431 Chinese citizens, according to the ministry.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

来源：资阳报